The purpose of the study is to see how well Nemtabrutinib works compared to the other two treatments in people who have not yet received treatment for their CLL or SLL. Participants will be randomly assigned to receive either Nemtabrutinib or one of the other two medications chosen by the study doctor. The study will last for a period of up to 108 weeks, during which participants will take the medication daily and attend regular check-ups to monitor their health and the progress of the disease.

Throughout the study, doctors will assess how the disease responds to the treatment and how long participants remain free from disease progression. They will also monitor overall survival and any side effects experienced by participants. The study aims to provide valuable information on the effectiveness and safety of Nemtabrutinib compared to the current standard treatments for CLL and SLL.

The purpose of the study is to learn about the safety of BIIB080 and whether it can improve symptoms in participants. Participants will receive the treatment through an injection into the spinal fluid, a method known as intrathecal use. The study will last for a period of 76 weeks, during which participants will be monitored for changes in their cognitive abilities and overall health. The study aims to understand how different doses of the treatment affect the symptoms of Alzheimer’s disease.

Throughout the study, participants will undergo various assessments to track their progress. These assessments include tests to measure memory and thinking skills, as well as monitoring for any side effects or adverse events. The study is designed to provide valuable information on the potential benefits and safety of BIIB080 for individuals with early stages of Alzheimer’s disease.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

The purpose of this study is to assess how effective and safe Plozasiran is in reducing fasting triglyceride levels in adults with severe hypertriglyceridemia. Participants in the study will receive either Plozasiran or a placebo, which is a substance with no active medication. The study will last for about 12 months, during which participants will receive regular injections and have their triglyceride levels monitored at various points to see how they change over time.

Throughout the study, participants will be closely monitored for any changes in their health and any side effects they might experience. The goal is to determine if Plozasiran can significantly lower triglyceride levels compared to the placebo, and to see if it helps more participants reach healthier triglyceride levels. This research could lead to a new treatment option for people with severe hypertriglyceridemia, potentially improving their health and reducing the risk of complications associated with high triglyceride levels.

The purpose of this study is to find out if ziltivekimab works better than placebo in reducing the risk of death from heart and blood vessel problems and preventing heart failure events such as hospital stays or urgent visits for worsening heart failure. The study will also look at other health outcomes including the combined risk of death from heart problems, heart attacks, and strokes, as well as how the treatment affects kidney function, quality of life, and inflammation levels in the body. Quality of life will be measured using questionnaires that ask about symptoms and daily activities.

During the study, participants will receive monthly injections for up to 48 months. The study will track various health events including hospitalizations for heart failure, deaths, heart attacks, strokes, and changes in heart and kidney function. Blood tests will be done to measure inflammation markers like hs-CRP and heart stress markers like NT-proBNP. Heart function will be checked using echocardiography, which is an ultrasound test that creates pictures of the heart. The study will continue until enough information has been collected to determine whether ziltivekimab is effective in helping people with this type of heart failure and inflammation.

The purpose of the study is to compare the effectiveness of different medication combinations in preventing the cancer from getting worse. One group will receive a combination of sotorasib, panitumumab, and FOLFIRI. FOLFIRI is a treatment plan that includes fluorouracil, irinotecan hydrochloride trihydrate, and calcium folinate, all of which are administered through intravenous use, meaning they are delivered directly into a vein. Another group will receive FOLFIRI either alone or combined with bevacizumab.

Participants will be assigned to one of these treatment groups to see which approach is better at managing the disease. The study will follow the progress of the cancer over time to observe how long the treatments keep the disease from spreading further or increasing in size.

Participants will be assigned to receive either olpasiran or a placebo through a subcutaneous injection, which means the medication is delivered into the fatty tissue just under the skin. During the study, researchers will monitor for various health events such as ischemic stroke, which is a blockage of blood flow to the brain, and cardiovascular death. The study will also track changes in the levels of lipoprotein (a) in the blood over time to see how the treatment affects this substance.

The purpose of this study is to compare how well odronextamab combined with chemotherapy works compared to rituximab combined with chemotherapy in people who have not received treatment for their follicular lymphoma before. The study will also look at whether odronextamab is safe and what side effects it may cause. The study is divided into two parts. Part 1 will test the safety of odronextamab when given with chemotherapy and will help determine the best dose to use. Part 2 will compare the two treatment combinations to see which one works better at helping patients achieve a complete response, which means that signs of cancer can no longer be detected.

During the study, participants will receive their assigned treatment through an infusion into a vein or by mouth, depending on the specific medicine. The study will monitor participants through various tests including imaging scans such as computed tomography or magnetic resonance imaging to measure how the disease responds to treatment. Participants will also be asked to complete questionnaires about their quality of life and any symptoms they experience. The study will track how long the cancer stays under control, whether it comes back, and how long participants live. Blood samples will be taken to measure drug levels in the body and to check if the body develops any immune response to the treatment.

The study will test a medication called rimegepant sulfate (also known as PF-07899801), which belongs to a group of medicines called calcitonin gene-related peptide antagonists. This medicine comes as an orodispersible tablet that dissolves in the mouth and is taken by mouth. The purpose is to determine if rimegepant sulfate works better than placebo in preventing migraines in adolescents with chronic migraine.

The study will last several months and will have two parts. In the first part, participants will receive either rimegepant sulfate or placebo without knowing which one they are taking. After this initial phase, there will be an extended period where all participants will receive the active medication. Throughout the study, participants will need to keep track of their headache days and complete questionnaires about how migraines affect their daily activities.

The purpose of this research is to test how safe bemarituzumab is and how well it works in treating different types of solid tumors. The study is divided into two parts. In the first part, doctors will closely monitor how patients respond to the medication and any side effects that may occur. In the second part, they will evaluate how effective the medication is at fighting the cancer.

During the study, patients will receive bemarituzumab through regular infusions. The doctors will track the progress of the treatment using different medical tests and imaging scans such as computed tomography (CT) or magnetic resonance imaging (MRI). They will monitor how the tumors respond to the treatment and keep track of any changes in the patient’s health throughout the study period.

The purpose of this study is to assess how well the Shingrix vaccine works over a long period, how safe it is, and how long the immune response lasts in older adults. Participants in the study will receive one or two additional doses of the vaccine. The study will follow participants for several years to monitor their health and the effectiveness of the vaccine in preventing shingles.

Throughout the study, participants will have regular check-ups to track their immune response and any side effects. The study will also look at the number of confirmed cases of shingles among participants and measure specific immune cells and antibodies that help protect against the virus. This information will help determine the long-term benefits and safety of the Shingrix vaccine for preventing shingles in older adults.

The purpose of the study is to evaluate how well Brensocatib can improve nasal symptoms in participants with CRSsNP. Participants will be randomly assigned to receive either Brensocatib or a placebo, and the study will be conducted in a double-blind manner, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. The study will last for 24 weeks, during which participants will take the medication daily and have regular check-ups to monitor their symptoms and overall health.

Throughout the study, various assessments will be conducted to measure changes in nasal symptoms, such as the Sinus Total Symptom Score and Nasal Congestion Scores. Additionally, the study will monitor any adverse events, changes in clinical laboratory test results, and other health indicators. The goal is to determine if Brensocatib is a safe and effective treatment option for improving the quality of life for those suffering from CRSsNP.

The purpose of this study is to see if the new treatment combination can improve the overall survival of patients with this type of cancer compared to the standard treatment. Participants in the study will be randomly assigned to receive either the new treatment or the standard treatment. The study will monitor the participants over time to assess the effectiveness and safety of the treatments. The study will also look at other factors such as how long the treatments can keep the cancer from getting worse and the overall response of the cancer to the treatments.

This study is important because it aims to find better treatment options for patients with advanced biliary tract cancer, which is a challenging condition to treat. By participating in this study, researchers hope to gather valuable information that could lead to improved outcomes for patients in the future. The study is expected to continue for several years to ensure comprehensive data collection and analysis.

Participants in the study will receive either Rina-S or one of several other treatments, which may include topotecan, glatiramer acetate, paclitaxel, doxorubicin hydrochloride, or gemcitabine hydrochloride. These treatments are given through an intravenous infusion, which means they are delivered directly into the bloodstream through a vein. The study will last for up to 36 months, during which time the participants’ health and response to the treatment will be closely monitored.

The purpose of the study is to determine how well Rina-S works compared to the other treatments in terms of delaying the progression of the cancer. The study will also look at other important factors, such as overall survival, the response of the cancer to the treatment, and the quality of life of the participants. This information will help doctors understand the best ways to treat platinum-resistant ovarian cancer in the future.

The purpose of this research is to determine how well RO7790121 works compared to placebo in helping patients maintain improvement of their Crohn’s Disease symptoms. The study involves two phases – an initial treatment phase (induction) followed by a longer maintenance phase where patients continue receiving either the study medication or placebo.

During the study, participants will receive regular doses of either RO7790121 or placebo through injections under the skin. The study is “double-blind,” which means neither the patients nor their doctors will know which treatment is being given. The effectiveness of the treatment will be measured by checking if patients achieve reduced disease activity and healing of the intestinal lining.

The purpose of the study is to assess how well frexalimab works compared to teriflunomide in reducing the frequency of relapses in participants with relapsing forms of multiple sclerosis. Participants will be randomly assigned to receive either frexalimab, teriflunomide, or a placebo. A placebo is a substance with no active medication, used to compare the effects of the actual drugs. The study will also involve the use of MRI scans, which are imaging tests that help visualize the brain and spinal cord, to monitor changes in the condition over time.

Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the effectiveness of the treatments. The study will last for a period of time, during which participants will be closely observed for any changes in their condition, including the number of relapses and any side effects they may experience. The goal is to gather information that could lead to improved treatment options for people living with multiple sclerosis.

The purpose of the study is to evaluate how effective elritercept is in reducing the number of red blood cell transfusions needed by participants. The study will involve participants receiving either the treatment or a placebo, and their progress will be monitored over a period of time. The main goal is to see if participants can achieve transfusion independence, meaning they do not need transfusions for at least eight weeks during the study period.

Participants will be closely monitored for any side effects or changes in their health, including laboratory tests, vital signs, and heart function tests. The study aims to provide valuable information on the safety and effectiveness of elritercept for treating transfusion-dependent anemia in people with myelodysplastic syndromes.

The purpose of the study is to compare the effectiveness of these treatments in patients who have not received prior treatment for their CLL or SLL. The study will look at how long patients live without their disease getting worse, which is known as progression-free survival. The trial will also explore how the treatment duration can be adjusted based on the measurement of individual residual disease, which refers to the small number of cancer cells that might remain after treatment.

Participants in the study will receive one of the treatment combinations for a set number of cycles. The study will monitor various outcomes, including the overall response to the treatment, the duration of the response, and the time until the next treatment is needed. Safety will also be closely monitored by tracking any adverse events. The study aims to improve treatment outcomes by tailoring the duration of therapy to each patient’s needs.

The purpose of the study is to compare how these two treatments work in the body, their effects on the disease, and their safety. Participants will receive either ABP 692 or Ocrevus, and the study will monitor how the treatments affect the number of new active brain lesions, which are areas of damage in the brain that can be seen using a special imaging technique called MRI (Magnetic Resonance Imaging). The study will last for about 48 weeks, with regular check-ups to assess the treatments’ effects and safety.

Throughout the study, participants will receive regular infusions and undergo various assessments to monitor their health and the progression of their condition. The goal is to determine if ABP 692 is as effective and safe as Ocrevus in treating RRMS. This information could help improve treatment options for people living with this condition.

The purpose of this study is to evaluate the safety and effectiveness of Tozorakimab in helping patients recover from severe viral lung infections. Participants in the study will receive either the Tozorakimab treatment or a placebo, in addition to the standard care they are already receiving. The study will monitor the participants over a period of time to see how many days they are alive and free from needing intensive care or extra oxygen, as well as other health outcomes.

Throughout the study, researchers will collect information on various health measures, such as the number of days participants are alive and not in the intensive care unit, and the time it takes for them to recover enough to stop needing extra oxygen. The study aims to provide valuable insights into how Tozorakimab can help improve the health and recovery of patients with severe viral lung infections.

The purpose of this study is to understand how the body processes these medications, as well as to assess their safety and how well they are tolerated by patients. The study involves participants from birth up to 18 years of age who are hospitalized with cUTI, including acute pyelonephritis. During the study, participants will receive the medication through an intravenous infusion, and their health will be monitored closely to observe how their bodies respond to the treatment.

Participants will be observed for any side effects or changes in their health, and various tests will be conducted to gather information about the medication’s effects. The study aims to provide valuable insights into the use of cefepime and enmetazobactam in treating complicated urinary tract infections in children and adolescents.

The purpose of the study is to determine which treatment approach provides better outcomes for patients with AML. Participants will be randomly assigned to receive either low-intensity therapy or high-dose chemotherapy. The study will monitor the time it takes for the disease to progress or for any complications to arise, as well as overall survival rates and response to treatment. Patients will also report on their quality of life during the study.

The trial will last several years, with an estimated end date in 2028. Participants will be closely monitored throughout the study to ensure their safety and to gather data on the effectiveness of the treatments. The study will also track any side effects experienced by participants. This information will help doctors understand which treatment options may be most beneficial for patients with AML in the future.

The purpose of the study is to evaluate how well AZD8630 works in preventing asthma flare-ups, known as exacerbations, in people whose asthma is not well controlled despite using other medications. The trial will last for 12 weeks, during which participants will take the medication once daily. The study will also assess the safety of AZD8630 and its impact on lung function, asthma symptoms, and overall quality of life.

Participants will use a device called the Saphira to inhale the medication. This device is designed to deliver the dry powder form of AZD8630 directly to the lungs. The study aims to provide valuable information on the potential benefits of AZD8630 for people with asthma who are at risk of experiencing severe symptoms. The trial will help determine if AZD8630 can be a safe and effective option for managing asthma in the future.

The purpose of the study is to evaluate how effective and safe ABP 206 is compared to OPDIVO® in patients who have not received any previous treatment for their advanced melanoma. Participants in the study will receive either ABP 206 or OPDIVO® for a period of up to 24 months. Some participants may receive a placebo, which is a substance with no active medication, to help compare the effects of the actual treatments. The study will monitor the response to the treatment, including any changes in the size of the melanoma, and will also track any side effects or immune reactions that may occur.

Throughout the study, participants will have regular check-ups to assess their health and the progress of their melanoma. The study aims to provide valuable information on the effectiveness of ABP 206 compared to OPDIVO® in treating unresectable or metastatic melanoma, potentially offering new insights into treatment options for this condition.

The purpose of the study is to determine if Frexalimab can help delay the progression of disability in individuals with this type of multiple sclerosis. Participants will be randomly assigned to receive either Frexalimab or a placebo, and neither the participants nor the researchers will know who is receiving which treatment. This is known as a double-blind study. The treatment will be given through an intravenous infusion, which means it will be delivered directly into a vein.

Throughout the study, participants will be monitored for changes in their condition, including any new or enlarging lesions in the brain as detected by MRI scans, changes in brain volume, and cognitive function. The study will also track any side effects or adverse events that may occur. The trial aims to provide valuable information on whether Frexalimab can be a beneficial treatment option for those with nonrelapsing secondary progressive multiple sclerosis.

The purpose of the study is to determine how effective Tolebrutinib is in slowing down the progression of disability in individuals with PPMS. Participants in the study will be randomly assigned to receive either Tolebrutinib or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are unbiased and reliable.

Throughout the study, participants will be monitored for changes in their condition, including any progression of disability. The study will also look at other factors such as changes in brain volume, cognitive function, and overall quality of life. Safety and tolerability of the medication will be closely observed to ensure the well-being of all participants. The study aims to provide valuable information on whether Tolebrutinib can be a beneficial treatment option for those living with PPMS.

The purpose of this study is to evaluate how well the new combination of acalabrutinib, venetoclax, and obinutuzumab works compared to the traditional chemotherapy options. Participants in the study will be randomly assigned to receive either the new combination treatment or one of the standard chemotherapy treatments. The study will monitor participants over a period of time to assess the progression of the disease and any side effects experienced. The medications will be administered either orally or through intravenous infusion, depending on the specific drug.

This trial is designed for individuals who have not received prior treatment for their CLL and do not have certain genetic mutations, specifically the del(17p) or TP53 mutation. The study aims to provide valuable information on whether the new treatment combination can offer better outcomes for patients with CLL compared to existing chemotherapy options. Participants will be closely monitored by healthcare professionals throughout the study to ensure their safety and to gather data on the effectiveness of the treatments.

The purpose of the study is to evaluate how well Pembrolizumab works in treating these specific types of lymphoma. Participants in the study will receive Pembrolizumab every six weeks. The study will monitor the response of the cancer to the treatment, as well as any side effects that may occur. The study aims to gather information on how effective Pembrolizumab is in shrinking or controlling the cancer.

Throughout the study, participants will undergo regular check-ups and tests to assess their health and the progress of the treatment. The study will continue for a period of time to ensure that enough data is collected to understand the effects of Pembrolizumab on these types of lymphoma. The results will help determine if Pembrolizumab can be a beneficial treatment option for patients with these conditions.

The purpose of the study is to compare the effectiveness of using Encorafenib and Cetuximab together with Pembrolizumab against using Pembrolizumab alone. Participants in the study will be randomly assigned to one of these two treatment groups. The study will last for up to 24 months, during which participants will receive their assigned treatment and have regular check-ups to monitor their health and the cancer’s response to the treatment.

Throughout the study, participants will have regular visits with the study team to assess their health, including blood tests and scans to check the cancer’s progress. The study aims to provide valuable information on whether the combination of these medications can offer better outcomes for patients with this specific type of metastatic colorectal cancer. The results could help improve treatment options for future patients with similar conditions.

The purpose of this study is to evaluate how well ofatumumab is tolerated and how safe it is when used over a long period. Participants in the study will receive ofatumumab as an injection under the skin once every four weeks. The study will monitor participants for any side effects or changes in their health, including any changes in their laboratory test results or vital signs. The study will also track the number of relapses participants experience and any changes in their level of disability over time.

Participants will be followed for up to 240 weeks, which is about 4.5 years, to gather comprehensive data on the long-term effects of ofatumumab. The study aims to provide valuable information on the potential benefits and risks of using ofatumumab for managing relapsing multiple sclerosis, helping to inform future treatment options for this condition.

Participants in the study will receive either acalabrutinib or another treatment selected by their doctor. The study will monitor how patients respond to the treatment over a period of time, which could last up to 72 weeks. The study will also look at how often patients need to stop their treatment due to heart-related issues or other serious side effects. Additionally, the study will track the overall survival of patients, which means the time from starting the study to the time of death from any cause.

The study aims to provide valuable information on the effectiveness and safety of acalabrutinib for patients with CLL and heart problems. By comparing it to other treatments, researchers hope to understand better which option might be more beneficial for these patients. The results could help guide future treatment decisions for people with similar health conditions.

The purpose of the study is to evaluate how the combination of Obicetrapib and Ezetimibe affects the volume of non-calcified plaques in the coronary arteries over a period of 18 months. Participants will undergo a special type of imaging called Coronary CT Angiography to measure changes in their coronary plaque characteristics. This imaging method provides detailed pictures of the heart’s blood vessels, helping researchers understand how the treatment impacts plaque buildup.

Participants in the study will be randomly assigned to receive either the combination treatment or a placebo. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual treatment or the placebo. This approach helps ensure that the results are unbiased. The study will last for 18 months, during which participants will have regular check-ups and imaging tests to monitor their heart health and the effects of the treatment.

Participants in the study will be randomly assigned to receive either Iptacopan or a placebo, which looks like the medication but does not contain the active ingredient. The study is designed to be double-blind, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo. This helps ensure that the results are not biased. The study will last for a total of 24 months, with an interim analysis at 9 months to assess the initial effects of the treatment.

Throughout the study, participants will have regular check-ups to monitor their health and the progression of their kidney disease. The main focus will be on measuring protein levels in the urine, which is an indicator of kidney function, and observing any changes in kidney function over time. The study aims to determine if Iptacopan can reduce protein levels in the urine and slow down the progression of IgA Nephropathy compared to the placebo. Participants will also be monitored for any side effects or adverse reactions to the treatment.

The purpose of the study is to evaluate whether Abelacimab is as effective as Apixaban in preventing the recurrence of VTE in patients with cancer over a period of six months. If Abelacimab proves to be at least as effective, the study will further assess if it might be even better. Participants in the study will receive either Abelacimab or Apixaban and will be monitored for any recurrence of VTE and any bleeding events during the six-month period.

This trial is designed to provide valuable information on the effectiveness and safety of these treatments for patients with cancer-related VTE. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered, but the evaluation of the results is blinded to ensure unbiased assessment. The trial aims to help improve treatment options for patients dealing with this serious condition.

Participants in the study will receive either Abelacimab or Fragmin® for a period of six months. The study is designed to monitor the recurrence of VTE and any bleeding events during this time. Abelacimab is administered through a method called subcutaneous use, which means it is injected under the skin. Similarly, Fragmin® is also given through subcutaneous injection. The study aims to determine if Abelacimab can prevent VTE recurrence as effectively as Fragmin® and, if successful, to see if it might be even better.

Throughout the study, participants will be closely monitored to track any occurrences of VTE and to ensure their safety. The study is open-label, meaning that both the participants and the researchers know which treatment is being administered. However, the evaluation of the study’s outcomes is blinded, meaning that the people assessing the results do not know which treatment the participants received, to ensure unbiased results. The study is expected to continue until 2025, providing valuable information on the effectiveness of Abelacimab in treating VTE in patients with GI or GU cancer.

The purpose of this study is to compare the effectiveness of the subcutaneous form of nivolumab to the intravenous form in patients who have already received other treatments for their cancer. Participants in the study will be randomly assigned to receive either the subcutaneous or intravenous form of nivolumab. The study will monitor how the medication is processed in the body and its effects on the cancer over time. Some participants may receive a placebo, which is a substance with no active medication, to help compare the results.

Throughout the study, participants will have regular check-ups to monitor their health and the progress of their cancer. The study aims to provide valuable information on whether the subcutaneous form of nivolumab is as effective as the intravenous form, potentially offering a more convenient treatment option for patients with advanced kidney cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s long-term effects and safety.

The purpose of the study is to validate the safety and tolerability of inhaled Furosemide in patients experiencing dyspnea. Participants will receive a single dose of inhaled Furosemide and will be monitored for any side effects. The study will also evaluate how well the treatments help reduce the sensation of breathlessness by using scales that measure the severity of dyspnea. These scales include the visual-analog scale (VAS) and the Borg scale, which are tools used to assess how patients perceive their breathing difficulties.

Throughout the study, participants will be asked to report any changes in their symptoms and any side effects they experience. The study aims to determine if the treatments can achieve a meaningful improvement in the participants’ breathing comfort. The trial is expected to run until early 2026, with recruitment starting in 2024.

The purpose of this research is to determine if depemokimab is effective in controlling HES when compared to placebo in people who are already receiving standard care. The study will last for 52 weeks, during which participants will receive either depemokimab injections or placebo injections. Some participants will also receive prednisolone tablets or matching placebo tablets as part of their treatment.

Throughout the study, doctors will monitor how often participants experience HES flares, which are periods when symptoms get worse or blood eosinophil counts increase. The medication will be provided in a pre-filled syringe for injection under the skin. Participants will be regularly checked for any changes in their condition and any effects of the treatment.

The study involves testing different doses of RMC-035 compared to placebo to find the most effective amount of medication for protecting kidney function. During the study, participants will receive either RMC-035 or placebo through an infusion into their veins. The maximum daily dose will be 120 milligrams, and the total treatment period will last up to 2 days.

After receiving the treatment, patients will be monitored for changes in their kidney function, particularly focusing on how well their kidneys are working 90 days after surgery. The medication being tested is a biological product that contains a modified version of a protein naturally found in the body. This protein has protective properties that may help prevent kidney damage during and after heart surgery.